Parion Sciences Selected for Platform Presentation at the NHLBI Regional Innovation Conference to be Held on September 22nd at the NC Biotech Center

2800 Meridian Parkway, Suite 195
Durham, North Carolina 27713
(919) 313-1180 (phone)
(919) 313-1190 (fax)

Paul Boucher
President, Parion Sciences
[email protected]

Durham, NC (September 10, 2014) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, was selected to present at the upcoming National Heart, Lung, and Blood Institute (NHLBI) Regional Innovation Conference in Durham, NC on Monday, September 22nd at the North Carolina Biotechnology Center. Parion’s President Paul Boucher will speak on behalf of the company.

Below is a link to more information on the conference:

About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects.